Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (131-140 of 334) with videos related to

Pageof 34
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 20, 2017
Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factorsFilip Poelaert, Valérie Fonteyne, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2022
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?Rachel M Glicksman, David A Palma, Matthew P Deek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2025
Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?"Carole Mercier, Charlotte Billiet, Piet Ost, et al.
Urologic Oncology|February 4, 2017
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapiesTom Claeys, Nicolaas Lumen, Candy Kumps, et al.
Radiation Oncology (London, England)|February 22, 2025
Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysisBrecht De Cooman, Tibaut Debacker, Thomas Adams, et al.
World Journal of Urology|February 3, 2020
Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trialRenée Bultijnck, Benedicte Deforche, Noëmi Borrey, et al.
European Urology Focus|May 11, 2026
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 9, 2018
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trialElke Rammant, Piet Ost, Martijn Swimberghe, et al.
World Journal of Urology|August 23, 2018
Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancerSarah Buelens, Elise De Bleser, Bert Dhondt, et al.
BMC Medical Genomics|July 8, 2020
Comparative analysis of somatic variant calling on matched FF and FFPE WGS samplesLouise de Schaetzen van Brienen, Maarten Larmuseau, Kim Van der Eecken, et al.
Pageof 34

Showing results (131-140 of 334) with videos related to

Sort By:
Pageof 34
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 20, 2017
Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factorsFilip Poelaert, Valérie Fonteyne, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2022
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?Rachel M Glicksman, David A Palma, Matthew P Deek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2025
Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?"Carole Mercier, Charlotte Billiet, Piet Ost, et al.
Urologic Oncology|February 4, 2017
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapiesTom Claeys, Nicolaas Lumen, Candy Kumps, et al.
Radiation Oncology (London, England)|February 22, 2025
Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysisBrecht De Cooman, Tibaut Debacker, Thomas Adams, et al.
World Journal of Urology|February 3, 2020
Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trialRenée Bultijnck, Benedicte Deforche, Noëmi Borrey, et al.
European Urology Focus|May 11, 2026
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate CancerBram De Laere, Alessio Crippa, Andrea Discacciati, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 9, 2018
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trialElke Rammant, Piet Ost, Martijn Swimberghe, et al.
World Journal of Urology|August 23, 2018
Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancerSarah Buelens, Elise De Bleser, Bert Dhondt, et al.
BMC Medical Genomics|July 8, 2020
Comparative analysis of somatic variant calling on matched FF and FFPE WGS samplesLouise de Schaetzen van Brienen, Maarten Larmuseau, Kim Van der Eecken, et al.
Pageof 34